Five-Grass Pollen Immunotherapy Tablet: An Update on the Latest Findings from Clinical Trials: An Interview with Olivier De Beaumont

Abstract

Interview by Jonathan Wilkinson (Managing Commissioning Editor, Future Science Group).

Olivier de Beaumont became Doctor of Medicine at the University of Paris Descartes in 1993. In the same year, he also took a Master of Health Economics degree at Paris Dauphine University. He is also a Master of Business Administration, ESCP Paris, 1999. At Stallergenes, he has been serving as Vice President/Head of Corporate Clinical Development since 2005, responsible for the clinical development plan, clinical operations, biometry and pharmacovigilance. In 2011, he took the responsibility of Senior Vice President Global Medical Affairs responsible for medical information and education, medical communication and nonregistration clinical studies. In 2014 he became Senior Vice President Global Scientific and Medical Affairs. From 2002 to 2005 he led the European business development of the world’s leading clinical research organization Quintiles, developing Phase I–IV clinical trial programs for pharmaceutical companies. Previous roles included: Chief Scientific Officer and cofounder of Direct Medica (2000–2002), product champion and lifecycle management at Aventis (1998–2000), medical affairs manager in oncology and respiratory diseases at corporate Rhone-Poulenc Rorer (1993–1998).

Disclaimer

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.

Financial & competing interests disclosure

O de Beaumont is an employee of Stallergenes. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.